3m Innovative Properties Company

Guilford Pharmaceuticals, Inc.

Eisai Inc.

Doris Stoermer

Joseph F Dellaria, Jr

Matthew R Radmer

Luke T Dressel

Jason D Bonk

Takashi Tsukamoto

Bernhard M Zimmermann

David T Amos

George W Griesgraber

Pavel Majer

Kyle J Lindstrom

Barbara S Slusher

Philip D Heppner

William H Moser

John R Jacobsen

Tushar A Kshirsagar

Joan T Moseman

James D Mendoza

Dilrukshi Vitharana

David S Hays

Shri Niwas

Weizheng Xu

Sonja S Mackey

Qun Liu

Daniel E Duffy

Joseph F Dellaria

Bunda Hin

The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation.

Immune response modifier conjugates

The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.

Immune response modifier compositions and methods

Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

Methods and intermediates useful for making compounds of the formula: and the preparation of compounds of Formula I, preferably including the formation of intermediate compounds of the formula: 

Ring closing and related methods and intermediates

Imidazopyridine compounds that contain an ether or thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.

Ether substituted imidazopyridines

The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&#x3b2; activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.

Thiolalkyl benzoic acid derivatives

This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&#x3b2; activity, inhibiting angiogenesis, and treating glutamate abnormalities, diabetic neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.

Thiol-based NAALADase inhibitors

This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&#x3b2; activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.

Hydroxamic acids and acyl hydroxamines as naaladase inhibitors

Growing community of inventors

Newbury Park, CA, United States of America

Doris Stoermer